Want to see FR:IVA full AI Analyst Report?
IVA Stock Chart & Stats
€3.82
€0.17(4.45%)
At close: 4:00 PM EDT
€3.82
€0.17(4.45%)
Day’s Range― - ―
52-Week Range€2.79 - €6.20
Previous CloseN/A
Volume253.81K
Average Volume (3M)416.07K
Market Cap
€897.69M
Enterprise Value€722.43
Total Cash (Recent Filing)€230.87M
Total Debt (Recent Filing)€59.86M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Sep 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume620,713
30 Day Avg. Volume416,066
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-25.87
Price to Sales (P/S)164.59
P/FCF Ratio-7.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.67Price Target Upside127.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€5.95M
Bulls Say, Bears Say
Bulls Say
Phase III EnrollmentCompleting a large, >90%-powered Phase III trial with ~1,000 patients materially reduces trial-level uncertainty and strengthens the ability to generate definitive efficacy evidence. A well-powered, intact study improves regulatory confidence and enhances partner negotiation leverage long term.
Cash Runway To ReadoutA reported cash balance sufficient to reach the planned top-line readout cushions near-term refinancing pressure and supports ongoing trial operations and regulatory/commercial preparedness. This capital runway preserves strategic optionality until pivotal data are available.
Clinical Differentiation & DesignationsPrior Phase II efficacy plus Breakthrough and Fast Track designations increase the probability of an efficient regulatory path and commercial interest. Demonstrated metabolic and fibrosis signals broaden potential indications and make the asset more attractive for partnerships or licensing.
Bears Say
Negative Equity & Cash BurnNegative equity and consistent operating/free cash outflows indicate accumulated losses have eroded the capital base, raising solvency and financing risk. This durable weakness limits strategic flexibility, increases dilution risk, and complicates long-term investment or commercialization plans.
Contingent Financing RelianceReliance on warrant exercise for extended runway creates material conditional financing risk. If investors don’t exercise, the company may need dilutive raises or cost cuts post‑readout, constraining R&D, commercial planning and bargaining power in partner or licensing discussions.
Safety / Regulatory ScrutinyDose-related weight gain and fluid retention are structural safety issues for a pan‑PPAR agent. Regulatory scrutiny or label limitations could require additional studies, restrict indications or dampen physician uptake, lowering long‑term commercial potential even with positive efficacy.
Inventiva News
IVA FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest stock price was €2.79 and its highest was €6.20 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €897.69M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Sep 25, 2026 which is in 50 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Mar 30, 2026. The company reported -€0.926 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.689.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA does not currently pay dividends.
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.33.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 236,280,200 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€0.926 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in FR:IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
€8.67
▲(127.05% Upside)